249 related articles for article (PubMed ID: 2616574)
1. Induced differentiation of murine erythroleukemia cells (MELC) by polar compounds: marked increased sensitivity of vincristine resistant MELC.
Marks PA; Michaeli J; Jackson J; Richon VM; Rifkind RA
Prog Clin Biol Res; 1989; 316B():171-81. PubMed ID: 2616574
[TBL] [Abstract][Full Text] [Related]
2. Hexamethylene bisacetamide-induced differentiation of transformed cells: molecular and cellular effects and therapeutic application.
Marks PA; Rifkind RA
Int J Cell Cloning; 1988 Jul; 6(4):230-40. PubMed ID: 3047266
[TBL] [Abstract][Full Text] [Related]
3. Changes in gene expression during hexamethylene bisacetamide induced erythroleukemia differentiation.
Marks PA; Ramsay R; Sheffery M; Rifkind RA
Prog Clin Biol Res; 1987; 251():253-68. PubMed ID: 3481077
[TBL] [Abstract][Full Text] [Related]
4. [Expression of protooncogenes c-myb and c-myc during the hexamethylene bisacetamide (HMBA)-induced commitment to terminal differentiation of murine erythroleukemia cells].
Chen ZX
Zhonghua Zhong Liu Za Zhi; 1991 Jul; 13(4):261-4. PubMed ID: 1806345
[TBL] [Abstract][Full Text] [Related]
5. Conversion of differentiation inducer resistance to differentiation inducer sensitivity in erythroleukemia cells.
Michaeli J; Lebedev YB; Richon VM; Chen ZX; Marks PA; Rifkind RA
Mol Cell Biol; 1990 Jul; 10(7):3535-40. PubMed ID: 1972544
[TBL] [Abstract][Full Text] [Related]
6. Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells.
Richon VM; Rifkind RA; Marks PA
Cell Growth Differ; 1992 Jul; 3(7):413-20. PubMed ID: 1419904
[TBL] [Abstract][Full Text] [Related]
7. Changes in p34cdc2 kinase activity and cyclin A during induced differentiation of murine erythroleukemia cells.
Kiyokawa H; Ngo L; Kurosaki T; Rifkind RA; Marks PA
Cell Growth Differ; 1992 Jun; 3(6):377-83. PubMed ID: 1419901
[TBL] [Abstract][Full Text] [Related]
8. Induced erythroleukemia differentiation: cellular and molecular aspects.
Rifkind RA; Sheffery M; Marks PA
Blood Cells; 1987; 13(1-2):277-84. PubMed ID: 3311222
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation.
Richon VM; Ramsay RG; Rifkind RA; Marks PA
Oncogene; 1989 Feb; 4(2):165-73. PubMed ID: 2648254
[TBL] [Abstract][Full Text] [Related]
10. Inducer-mediated commitment of murine erythroleukemia cells to differentiation: a multistep process.
Chen Z; Banks J; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 1982 Jan; 79(2):471-5. PubMed ID: 6952199
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of erythroleukemia cells selected for vincristine resistance that have accelerated inducer-mediated differentiation.
Richon VM; Weich N; Leng L; Kiyokawa H; Ngo L; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1666-70. PubMed ID: 1672043
[TBL] [Abstract][Full Text] [Related]
12. Changes in gene expression associated with induced differentiation of erythroleukemia: protooncogenes, globin genes, and cell division.
Ramsay RG; Ikeda K; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 1986 Sep; 83(18):6849-53. PubMed ID: 3462732
[TBL] [Abstract][Full Text] [Related]
13. Modulation of gene expression during terminal cell differentiation: murine erythroleukemia.
Marks PA; Murate T; Kaneda T; Ravetch J; Rifkind RA
Symp Fundam Cancer Res; 1984; 37():327-40. PubMed ID: 6084863
[TBL] [Abstract][Full Text] [Related]
14. Modulation of gene expression during terminal cell differentiation.
Marks PA; Sheffery M; Rifkind RA
Prog Clin Biol Res; 1985; 191():185-203. PubMed ID: 3901038
[TBL] [Abstract][Full Text] [Related]
15. Vincristine-resistant erythroleukemia cell line has marked increased sensitivity to hexamethylenebisacetamide-induced differentiation.
Melloni E; Pontremoli S; Damiani G; Viotti P; Weich N; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 1988 Jun; 85(11):3835-9. PubMed ID: 3163801
[TBL] [Abstract][Full Text] [Related]
16. Antagonistic effect of butyrate on hexamethylene bisacetamide induced differentiation of murine erythroleukemia cells.
Corin RE; Haspel HC; Peretz AM; Sonenberg M; Rifkind RA
Cancer Res; 1986 Mar; 46(3):1136-41. PubMed ID: 3455880
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide-releasing agents and cGMP analogues inhibit murine erythroleukemia cell differentiation and suppress erythroid-specific gene expression: correlation with decreased DNA binding of NF-E2 and altered c-myb mRNA expression.
Suhasini M; Boss GR; Pascual FE; Pilz RB
Cell Growth Differ; 1995 Dec; 6(12):1559-66. PubMed ID: 9019161
[TBL] [Abstract][Full Text] [Related]
18. Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide.
Waxman S; Scher BM; Hellinger N; Scher W
Cancer Res; 1990 Jul; 50(13):3878-87. PubMed ID: 2354439
[TBL] [Abstract][Full Text] [Related]
19. A rise and fall in 1,2-diacylglycerol content signal hexamethylene bisacetamide-induced erythropoiesis.
Michaeli J; Busquets X; Orlow I; Younes A; Colomer D; Marks PA; Rifkind RA; Kolesnick RN
J Biol Chem; 1992 Nov; 267(33):23463-6. PubMed ID: 1429688
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of protein kinase C isozymes and erythroleukemia cell differentiation.
Melloni E; Pontremoli S; Viotti PL; Patrone M; Marks PA; Rifkind RA
J Biol Chem; 1989 Nov; 264(31):18414-8. PubMed ID: 2808382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
